Ferring Pharmaceuticals

Ferring Pharmaceuticals

Argentina - Buenos Aires
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Small Molecule Manufacturing

Ferring Pharmaceuticals is a life sciences company focused on Small Molecule Manufacturing.

Neurology
Employees
5000+
Open Jobs
133

Products & Portfolio (9)

18 discontinued products not shown

ACTHREL
corticorelin ovine triflutate
LOE Approaching
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Pharmacodynamics In normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition, intravenous administration of corticorelin to normal subjects causes a concomitant and prolonged release of the related proopiomelanocortin peptides β- and γ-lipotropins (β -and γ-LPH) and β-endorphin (β -END). A number of dose-response studies have been performed on normal subjects using a range of corticorelin doses. In one study, doses of corticorelin ranging from 0.001 to 30 mcg/kg body weight were administered to 29 healthy volunteers. Blood samples were taken over a 2-hour period for determination of plasma ACTH and cortisol concentrations. There was a direct dose-dependent relationship that was more pronounced for ACTH than for cortisol. The threshold dose was 0.03 mcg/kg, the half-maximal dose was 0.3-1.0 mcg/kg and the maximally effective dose was 3-10 mcg/kg. Plasma ACTH levels in normal subjects increased 2 minutes after injection of corticorelin doses of ≥0.3 mcg/kg and reached peak levels after 10-15 minutes. Plasma cortisol levels increased within 10 minutes and reached peak levels at 30 to 60 minutes. As the dose of corticorelin was increased, the rises in plasma ACTH and cortisol were more sustained, showing a biphasic response with a second lower peak at 2-3 hours after injection. Similar results were found in another study using 0.3, 3.0, and 30 mcg/kg doses. The duration of mean plasma ACTH increase after injection of 0.3, 3.0, and 30 mcg/kg was 4, 7, and 8 hours, respectively. The effect on plasma cortisol was similar, but more prolonged. Because there are differences in basal levels and peak response levels following a.m. or p.m. administration, it is recommended that subsequent evaluations in the same patient using the corticorelin stimulation test be carried out at the same time of day as the original evaluation. Baseline ACTH and cortisol levels are usually higher in the morning. Pooled ACTH values from normal unstressed subjects (n=119) were 25 ± 7 pg/mL in the a.m. and 10 ± 3 in the p.m.; similar pooled cortisol values (n=170) were 11 ± 3 mcg/dL in the a.m. and 4 ± 2 mcg/dL in the p.m. The normal unstressed person has about seven to ten secretory episodes of ACTH each day. Most of them occur in the early morning hours and are responsible for the morning plasma cortisol surge. The following figure shows the daily circadian rhythm of ACTH and cortisol secretions in a normal unstressed person. Insulin, plasma renin activity, prolactin, and growth hormone release are not affected by corticorelin administration in humans. Continuous 24-hour infusion of corticorelin (0.5, 1.0, and 3.0 mcg/kg/hr) increased plasma ACTH concentrations to a plateau of 15-20 pg/mL by the third hour and urinary-free cortisol reaches 173 ± 43 mcg/dL by 24 hours, comparable to those levels observed in patients with major depres
1996
30
BRAVELLE
urofollitropin
LOE Approaching
Subcutaneous · Injectable
2002
30
CERVIDIL
dinoprostone
LOE Approaching
VAGINAL · INSERT, EXTENDED RELEASE
hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F 2α ( PGF 2α), which sensitizes the myometrium to endogenous or exogenously administered oxytocin. Available evidence indicates that dinoprostone, in the concentrations found during the early part of labor, plays an important role in cervical ripening without affecting uterine contractions. In most patients, local effects of CERVIDIL on the cervix include changes in the tissue consistency, dilatation and effacement. Some women experience systemic effects, including uterine tachysystole, and uterine hypersystole/hypertonicity, as a result dinoprostone or PGF 2α mediated sensitization of the myometrium to oxytocin [see ] .
1995
30
CLENPIQ
sodium picosulfate, magnesium oxide, and anhydrous citric acid
Peak
ORAL · SOLUTION
Acidifying Activity
2017
0
DDAVP
desmopressin acetate
LOE Approaching
ORAL · TABLET
CLINICAL PHARMACOLOGY DDAVP Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg produced clinically significant antidiuretic effects. In most patients, doses of 0.1 mg to 0.2 mg produced optimal antidiuretic effects lasting up to eight hours. With doses of 0.4 mg, antidiuretic effects were observed for up to 12 hours; measurements beyond 12 hours were not recorded. Increasing oral doses produced dose dependent increases in the plasma levels of DDAVP (desmopressin acetate). The plasma half-life of DDAVP followed a monoexponential time course with t 1/2 values of 1.5 to 2.5 hours which was independent of dose. The bioavailability of DDAVP oral tablets is about 5% compared to intranasal DDAVP, and about 0.16% compared to intravenous DDAVP. The time to reach maximum plasma DDAVP levels ranged from 0.9 to 1.5 hours following oral or intranasal administration, respectively. Following administration of DDAVP Tablets , the onset of antidiuretic effect occurs at around 1 hour, and it reaches a maximum at about 4 to 7 hours based on the measurement of increased urine osmolality. The use of DDAVP Tablets in patients with an established diagnosis will result in a reduction in urinary output with an accompanying increase in urine osmolality. These effects usually will allow resumption of a more normal life style, with a decrease in urinary frequency and nocturia. There are reports of an occasional change in response to the intranasal formulations of DDAVP (DDAVP Nasal Spray and DDAVP Rhinal Tube). Usually, the change occurred over a period of time greater than six months. This change may be due to decreased responsiveness, or to shortened duration of effect. There is no evidence that this effect is due to the development of binding antibodies, but may be due to a local inactivation of the peptide. No lessening of effect was observed in the 46 patients who were treated with DDAVP Tablets for 12 to 44 months and no serum antibodies to desmopressin were detected. The change in structure of arginine vasopressin to desmopressin acetate resulted in less vasopressor activity and decreased action on visceral smooth muscle relative to enhanced antidiuretic activity. Consequently, clinically effective antidiuretic doses are usually below the threshold for effects on vascular or visceral smooth muscle. In the four long-term studies of DDAVP Tablets , no increases in blood pressure in 46 patients receiving DDAVP Tablets for periods of 12 to 44 months were reported. In one study, the pharmacodynamic characteristics of DDAVP Tablets and intranasal formulation were compared during an 8-hour dosing interval at steady state. The doses administered to 36 hydrated (water loaded) healthy male adult volunteers every 8 hours were 0.1, 0.2, 0.4 mg orally and 0.01 mg intra
primary nocturnal enuresis
1995
30
ENDOMETRIN
progesterone
LOE Approaching
VAGINAL · INSERT
ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.
2007
30
FIRMAGON
degarelix
Peak
SUBCUTANEOUS · POWDER
antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
prostate cancer
2008
0
MENOPUR
menotropins
LOE Approaching
SUBCUTANEOUS · INJECTABLE
MENOPUR, administered for 7 to 20 days, produces ovarian follicular growth and maturation in women who do not have primary ovarian failure. Treatment with MENOPUR in most instances results only in follicular growth and maturation. When sufficient follicular maturation has occurred, hCG must be given to induce ovulation.
2004
30
ZOMACTON
somatropin
LOE Approaching
INJECTION · INJECTABLE
1995
30

Pipeline & Clinical Trials

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectivene
Infertility
N/A
Clinical Trials (1)
NCT07029451To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
N/A
Degarelix Cohort
Prostate Cancer
N/A
Clinical Trials (1)
NCT05181800FIRMAGON® Intensive Drug Monitoring
N/A
N/A
Clinical Trials (1)
NCT05835219REBYOTA™ Prospective Registry
N/A
menotropin
Infertility
N/A
Clinical Trials (1)
NCT02018159An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos
N/A
N/A
Clinical Trials (1)
NCT04499495Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea
N/A
N/A
Clinical Trials (1)
NCT02368730Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures
N/A
AdhesioRT
Fertility
N/A
Clinical Trials (1)
NCT04840121Personalizing Window of Implantation During Frozen Embryo Transfer
N/A
N/A
Clinical Trials (1)
NCT01861236Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
N/A
whole-genome sequencing
Diminished Ovarian Reserve
N/A
Clinical Trials (1)
NCT04711772Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
N/A
N/A
Clinical Trials (1)
NCT03393780Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures
N/A
N/A
Clinical Trials (1)
NCT02229253Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
N/A
AURORA-Donor
Infertility
N/A
Clinical Trials (1)
NCT06280677Aurora Test for ART Donor Patients (AURORA-Donor)
N/A
Low Residue Diet
Colonoscopy Preparation
N/A
Clinical Trials (1)
NCT04150133Effects and Tolerability With Clenpiq and Low Residue Diet
N/A
This study will evaluate a new clinical scoring system in patients receiving routine treatment
Crohn's Disease
N/A
Clinical Trials (1)
NCT02193048Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
N/A
Presence of Toxins from Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm I
Exposure to Toxins from Smoking
N/A
Clinical Trials (1)
NCT03414567Presence of Toxins from Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm Injection Treatment
N/A
N/A
Clinical Trials (1)
NCT02886598Safety and Efficacy of Firmagon® (Degarelix) for Injection
N/A
N/A
Clinical Trials (1)
NCT04256785Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
N/A
N/A
Clinical Trials (1)
NCT03274973Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
N/A
N/A
Clinical Trials (1)
NCT02234089Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
N/A
N/A
Clinical Trials (1)
NCT03941665Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients
N/A
N/A
Clinical Trials (1)
NCT02261636Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment
N/A
Hypofraction
Prostate Cancer
N/A
Clinical Trials (1)
NCT01851018Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment
N/A
Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative
Ulcerative Colitis
N/A
Clinical Trials (1)
NCT01387698Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative Colitis
N/A
N/A
Clinical Trials (1)
NCT03193645Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
N/A
N/A
Clinical Trials (1)
NCT05189327Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan
N/A
N/A
Clinical Trials (1)
NCT00969501Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)
N/A
A Study of Pentasa in Patients With Ulcerative Colitis
Ulcerative Colitis
N/A
Clinical Trials (1)
NCT01104753A Study of Pentasa in Patients With Ulcerative Colitis
N/A
Compliance and Efficacy in the Use of PICOPREP®
Bowel Cleanliness
N/A
Clinical Trials (1)
NCT01220453Compliance and Efficacy in the Use of PICOPREP®
N/A
Saliva sample collection for genetic analyses
Prostate Cancer
N/A
Clinical Trials (1)
NCT02440802Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer
N/A
N/A
Clinical Trials (1)
NCT00379236A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee
N/A
hMG-HP/r-FSH
Sterility
N/A
Clinical Trials (1)
NCT01330771Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
N/A
N/A
Clinical Trials (1)
NCT01256788Post-op Treatment With Hyaluronic Acid Injections
N/A
N/A
Clinical Trials (1)
NCT04503707Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice
N/A
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted
Infertility
N/A
Clinical Trials (1)
NCT06545877REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
N/A
N/A
Clinical Trials (1)
NCT03028415AMPLEX Ankle Fusion and Hindfoot
N/A
Coenzyme Q10 concomitant treatment
Aneuploidy
N/A
Clinical Trials (1)
NCT01048385The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization
N/A
N/A
Clinical Trials (1)
NCT01703728Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.
N/A
Low FODMAP diet
eHealth
N/A
Clinical Trials (1)
NCT03586622One Year Home Monitoring and Treatment of IBS Patients
N/A
Sodium Picosulfate, Magnesium Oxide and Citric Acid
Bowel Cleansing
N/A
Clinical Trials (1)
NCT03631446Drug Use-Results Survey on Picoprep® Combination Powder
N/A
Chondroitin Sulfate Staining
Bladder Cancer
N/A
Clinical Trials (1)
NCT05400291Gag-layer in the Urothelium of the Human Upper Urinary Tract
N/A
Single Embryo Transfer
Infertility
N/A
Clinical Trials (1)
NCT01408433Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer
N/A
Estradiol / Progesterone
Infertility
N/A
Clinical Trials (1)
NCT05232344Sexual Intercourse and Vaginal Absorption of Progesterone
N/A
Quality of Life With TESTIM®
Hypogonadism
N/A
Clinical Trials (1)
NCT01148433Quality of Life With TESTIM®
N/A
N/A
Clinical Trials (1)
NCT01731028Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®
N/A
No intervention
Bowel Cleansing
N/A
Clinical Trials (1)
NCT04852120Compound Sodium Picosulfate Granules for Bowel Preparation in Chinese Population
N/A
hMG-HP
Sterility
N/A
Clinical Trials (1)
NCT01330784Assessment of the Therapeutic Utility of hMG-HP
N/A
N/A
Clinical Trials (1)
NCT01517607Mesalazine (PENTASA®) in Ulcerative Colitis
N/A
N/A
Clinical Trials (1)
NCT02068560The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
N/A
N/A
Clinical Trials (1)
NCT05499052Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
N/A
N/A
Clinical Trials (1)
NCT00930319Effectiveness and Safety of Firmagon®
N/A

Open Jobs (133)

Global Rewards Operations Analyst

Lisbon, Portugal
23h ago

Ausbildung zum Pharmakanten (m/w/d)

Kiel, Germany
23h ago

Executive - Regulatory Affairs & Pharmacovigilance

Mumbai, India
Pharmacovigilance
23h ago

IT Governance and Portfolio Analyst

Lisbon, Portugal
23h ago

Regulatory Affairs Associate

Istanbul, Turkey
Regulatory Affairs
23h ago

Key Account Manager, Uro-Oncology - South Florida

Miami, Florida, United States
Commercial
23h ago
$173K - $232K/yr

Supply Chain and Procurement Controller

Hvidovre, Denmark
Supply Chain
23h ago

Customer Order Management Specialist

Lisbon, Portugal
23h ago

Senior Medical Science Liaison

Bangkok, Thailand
Medical Affairs
23h ago

Junior Techniker (m/w/d)

Kiel, Germany
Yesterday

Student Assistant Position in PMO Office at Ferring Pharmaceuticals

Kastrup, Denmark
Project Management
Yesterday

Product Specialist (UROGI-Upper Southern Region & Chonburi)

Bangkok, Thailand
Commercial
Yesterday

Global Supply Planner

Zhongshan, China
Yesterday

Principal Enterprise Architect

Lisbon, Portugal
Yesterday

Regional Sales Specialist, Uro-Oncology - MidAtlantic

Pittsburgh, Pennsylvania, United States
Commercial
Yesterday
$120K - $170K/yr

Senior officer

Hyderabad, India
Yesterday

Global Regulatory Affairs Manager, 1-year contract

Kastrup, Denmark
Regulatory Affairs
Yesterday

Laboratory Assistant (m/w/d)

Kiel, Germany
Research & Development
Yesterday

Director Quality Control (m/w/d)

Kiel, Germany
Manufacturing
Yesterday

Sales Representative

Taipei, Taiwan
Commercial
Yesterday

Coordinatrice / Coordinateur Supply France

Gentilly, France
2d ago

Tender management & Supply chain coordinator

Anderlecht, Belgium
Supply Chain
2d ago

Manager, Specialty Medicine Central

Ferring Japan
3d ago

Sr. Manager, Commercial Learning and Development - Orthopaedics

Parsippany, New Jersey, United States
Commercial
4d ago
$150K - $180K/yr

Sr. Manager, Commercial Learning and Development - Market Access

Parsippany, New Jersey, United States
Commercial
4d ago
$150K - $180K/yr
View all 133 open positions →
Interview Prep Quick Facts
Founded: 2024
Portfolio: 27 approved products, 150 clinical trials
Top TAs: Oncology, Immunology, Women's Health
Open Roles: 133 active jobs
Portfolio Health
Pre-Launch1 (4%)
Peak4 (15%)
LOE Approaching22 (81%)
27 total products
Therapeutic Area Focus
Oncology
1 marketed73 pipeline
Immunology
35 pipeline
Women's Health
1 marketed16 pipeline
Endocrinology
14 pipeline
Metabolic Diseases
3 marketed2 pipeline
Cardiovascular
2 pipeline
Nephrology
1 marketed
Marketed
Pipeline

Hiring Trend

Actively Hiring
133
Open Roles
+100
Added
-7
Filled/Removed

Based on last 4 crawl cycles